Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug

BioNTech (NASDAQ:BNTX) received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its product candidate BNT211 in the third- or later-line treatment of testicular germ cell tumors.

The European regulatory grant is supported by the positive preliminary data readout from ongoing phase 1/2 study demonstrating an encouraging safety profile and early signs of anti-tumor activity in testicular cancer patients that was presented at the AACR Annual Meeting in April 2022.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.